Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 2 January 2026 - 6 January 2026

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors The update…
6 January 2026
···
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

NEW YORK, Jan 6, 2026, 08:19 EST — Premarket Cyclerion Therapeutics Inc shares jumped about 46% to around $2.01 in premarket trading on Tuesday after the company announced an expanded strategic collaboration with Medsteer to advance its closed-loop anesthetic platform, CYC-126. Benzinga The move matters because Cyclerion is trying to pair an anesthetic-based approach with a device-and-software system that adjusts…
6 January 2026
·····
GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

GSK stock rises after Japan greenlights twice-yearly Exdensur for severe asthma, nasal polyps

London, January 6, 2026, 09:03 GMT — Regular session GSK plc shares rose nearly 1% in early London trade on Tuesday after the drugmaker said Japan had approved its bronchial asthma treatment Exdensur. Shares were up 0.96% at 1,838 pence by 0830 GMT. Sharecast The decision lands as investors weigh whether GSK’s next wave of respiratory launches can broaden growth…
6 January 2026
···
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

New York, Jan 5, 2026, 14:59 EST — Regular session Thermo Fisher Scientific Inc shares rose about 2.4% in afternoon trading on Monday after Evercore ISI raised its price target to $650 from $610 and kept an “outperform” rating, a call that signals expectations for the stock to beat the broader market. The stock was last up 2.4% at $606.63,…
5 January 2026
·····
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms

New York, January 5, 2026, 14:30 (EST) — Regular session BridgeBio Pharma shares slid 7.5% to $72.34 in afternoon trading on Monday after opening at $78.44 and touching $79.24 earlier in the session. The drop outpaced a roughly 2.2% decline in the SPDR S&P Biotech ETF, a broad gauge of U.S. biotech stocks. The move lands just ahead of a…
5 January 2026
·····
Thermo Fisher (TMO) stock closes higher into 2026 — what to watch before Jan. 29 earnings

Thermo Fisher (TMO) stock closes higher into 2026 — what to watch before Jan. 29 earnings

NEW YORK, January 4, 2026, 19:53 ET — Market closed Thermo Fisher Scientific Inc shares closed Friday up about 2.3% at $592.51, beating the broader market’s modest advance in the first session of 2026. Reuters The move matters heading into Monday because investors are rotating from thin holiday trade into a January calendar packed with economic data and the start…
5 January 2026
·····
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

NEW YORK, Jan 3, 2026, 20:55 ET — Market closed Wave Life Sciences Ltd (WVE) shares closed down 6.2% on Friday at $15.95, ending the first full U.S. trading session of 2026 with a sharp pullback. The slide matters because Wave has become an event-driven obesity trade after a December clinical update on its experimental fat-loss drug drew heavy attention…
4 January 2026
····
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next

NEW YORK, Jan 2, 2026, 14:37 ET — Regular session Shares of Spyre Therapeutics, Inc. slid about 7% on Friday, falling to $30.48 in afternoon trading after touching a session low of $30.11. The stock opened at $32.76 and was last down $2.28 on the day. The move left Spyre underperforming the broader biotech tape, with the SPDR S&P Biotech…
2 January 2026
·····
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

NEW YORK, January 2, 2026, 14:13 ET — Regular session Wave Life Sciences Ltd shares slid on Friday, giving back part of last month’s obesity-driven run as the biotech sector wobbled in the first U.S. session of 2026. The stock was down about 8.5% at $15.55 as of 2:13 p.m. ET. The retreat matters because Wave has become a high-volatility…
2 January 2026
·····
INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

NEW YORK, Jan 2, 2026, 11:40 ET — Regular session Shares of Intelligent Bio Solutions Inc slid on Friday as investors digested the micro-cap medtech company’s $10 million private placement announced late Wednesday. The stock was down 12.1% at $8.38 by 11:25 a.m. ET. Benzinga The pullback comes after the stock more than doubled on Dec. 31 following news of…
2 January 2026
·····
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

NEW YORK, January 1, 2026, 21:17 ET — Market closed Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. New York Stock Exchange The year-end move…
2 January 2026
·····
1 … 5 6 7 8 9 … 24

Stock Market Today

  • Teacher Retirement System of Texas Boosts Pfizer Holdings by 32.3% in Q3
    February 2, 2026, 10:44 AM EST. Teacher Retirement System of Texas increased its Pfizer Inc. (NYSE:PFE) shares by 32.3%, acquiring 675,419 shares to hold 2.76 million shares worth $70.43 million at quarter-end. Other investors like Brighton Jones LLC and Revolve Wealth Partners also raised stakes. Pfizer reported quarterly earnings of $0.87 per share, surpassing estimates by $0.08, with net margin at 15.65%. Revenue stood at $16.65 billion, slightly below expectations. The company projects 2025 earnings per share between $3.00 and $3.15. Pfizer's stock recently traded near a 52-week high of $27.69 with a market cap of $148.34 billion. Institutional investors hold 68.36% of shares, reflecting strong confidence amid mixed earnings and moderate revenue performance.
Go toTop